<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534897</url>
  </required_header>
  <id_info>
    <org_study_id>11-337</org_study_id>
    <nct_id>NCT01534897</nct_id>
  </id_info>
  <brief_title>Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436</brief_title>
  <official_title>Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radioactive iodine therapy is often part of the standard treatment for Papillary Thyroid
      Carcinoma (PTC) patients. However, in many patients, tumors develop a resistance or no longer
      respond to radioactive iodine therapy (iodine-refractory). Several lines of evidence suggest
      that blocking the BRAF gene may help to re-sensitize the tumors to radioactive iodine. BRAF
      is a protein that plays a central role in the growth and survival of cancer cells in some
      types of PTC. The investigational drug GSK2118436 may work by blocking the BRAF protein in
      cancer cells lines and tumors that have a mutated BRAF gene.

      In this research study, the investigators are looking to see if GSK2118436 can re-sensitize
      iodine-refractory PTC to radioactive iodine therapy. The investigators are also looking at
      the safety of adding GSK2118436 to radioactive iodine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      You will take GSK2118436 capsules by mouth for 28 straight days. If your Day 28 whole body
      radioactive iodine scan demonstrates significant uptake of iodine, you will take GSK2118436
      for an additional 14 days (Days 29-42). You will be given a drug diary to record when you
      take GSK2118436. This diary will also contain instructions on how to take GSK2118436.

      Prior to Day 1

        -  Optional fine needle aspirate (pre-treatment) Day 1

        -  Vital signs

        -  Routine blood tests (2 tablespoons)

        -  Research blood sample for Circulating Tumor Cells (CTCs). (4 teaspoons of blood)

        -  Optional research blood sample for CTCs 4-6 hours after the first dose of GSK2118436

      Day 2:

        -  Optional research blood sample for CTCs 4-6 hours after the first dose of GSK2118436 Day
           3-5: Research blood sample for CTCs Days 8 and 15

        -  Vital signs

        -  Routine blood tests (2 tablespoons)

        -  Research blood sample for CTCs. (4 teaspoons of blood)

        -  Optional fine needle aspirate (Day 15 only) Low Iodine Diet: You will begin a low iodine
           diet on Day 15, in preparation for Day 23 when you will receive radioactive iodine
           (131I). The study team will provide you with instructions on this diet. The low iodine
           diet will be continued until the whole body scan is complete. For those participants who
           will receive a therapeutic dose of radioactive iodine on Day 37, the low iodine diet
           will be continued until the Day 42 whole body scan is complete.

      Days 21 and 22: The drug thyrogen will be administered as in injection into your buttocks on
      Days 21 and 22 in preparation for your whole body radioactive iodine scan on Day 28. Thyrogen
      is used as a diagnostic tool to help determine the status of your cancer and is approved for
      use in thyroid cancer patients.

      Day 23: To prepare for the whole body radioactive iodine scan, you will be asked to swallow a
      capsule of radioactive iodine which will be absorbed by any remaining thyroid cells in your
      body. Radioactive iodine is approved for use in thyroid cancer patients. You will then be
      asked to return for the scan on Day 28.You will be asked to sign a separate consent for the
      radioactive iodine.

      Days 1-28:

        -  Optional repeat fine needle aspirate Day 28

        -  Whole body radioactive iodine scan to assess your thyroid cancer

      If your Day 28 whole body radioactive iodine scan demonstrates significant uptake of iodine,
      you will have the following tests done within 24 hours:

        -  Vital signs

        -  Routine blood tests (2 tablespoons)

        -  Research blood sample for CTCs. (4 teaspoons of blood)

        -  An injection of a therapeutic dose of radioactive iodine will be administered. If your
           Day 28 whole body radioactive iodine scan does not demonstrate significant uptake of
           iodine, you will be removed from the research study. You will have a 3 month follow up
           appointment as outlined below.

      If your Day 28 whole body radioactive iodine scan demonstrates significant uptake of iodine,
      you will continue treatment with GSK2118436 and have the following study visits:

      Days 35 and 36: The drug thyrogen will be administered as in injection into your buttocks on
      Days 35 and 36 in preparation for your whole body radioactive iodine scan on Day 42.

      Day 37: You will be given a therapeutic dose of radioactive iodine. You will be given a
      separate consent form to sign for your radioactive iodine treatment. You will then be asked
      to return for the whole body radioactive iodine scan on Day 42.

      Day 39:

        -  Vital signs

        -  Routine blood tests (1 tablespoon)

      Day 42:

        -  Whole body radioactive iodine scan

        -  Research blood sample for CTCs. (4 teaspoons of blood)

      After the final dose of the study drug: All participants will have a follow up visit 3 months
      after you stop the study drug. You will have the following tests at this visit:

        -  Routine blood tests (2 tablespoons)

        -  Research blood sample for CTCs. (4 teaspoons of blood)

        -  An assessment of your tumor by CT scan or PET/CT scan of your neck, chest, abdomen and
           pelvis.

        -  Those participants who had a therapeutic dose of radioactive iodine on Day 37 will have
           a whole body radioactive iodine scan.

        -  Optional fine needle aspirate
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased Radioiodine Uptake</measure>
    <time_frame>25 days after start of Dabrafenib (GSK2118436)</time_frame>
    <description>Number of patients with radioiodine-refractory metastatic BRAF V600E-mutant PTC who have increased radioiodine uptake in their disease sites while on dabrafenib. Radioiodine uptake is assessed by whole body scan and areas of interest are identified by nuclear medicine physicians.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Analysis as Number of Participants With Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the safety and tolerability, as determined by adverse event and serious adverse event reporting, of GSK2118436 in combination with whole body iodine scans (all patients) and treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit as Measured by Change in Tumor Size</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate clinical benefit as measured by objective response rate per modified RECIST 1.1, which assesses changes in size of measurable tumors. (per RECIST, a partial response (PR) = at least 30% decrease in size of tumor; progressive disease (PD) = at least 20% increase in size of tumor; stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Complete the Study With Minimal Delays and no Dose Reductions</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the feasibility of: (a) administering GSK2118436 for 28 days in patients with BRAF V600E-mutant PTC, prior to whole body iodine scanning (all patients); and (b) administering GSK2118436 for an additional 14 days, prior to administering treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake after 28 days of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit as Measured by Change in Thyroglobulin Level</measure>
    <time_frame>3 months after radioiodine therapy</time_frame>
    <description>To evaluate clinical benefit as measured by change in serum tumor marker, thyroglobulin. Rising thyroglobulin is generally indicative of tumor growth.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Papillary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>GSK2118436</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2118436</intervention_name>
    <description>150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)</description>
    <arm_group_label>GSK2118436</arm_group_label>
    <other_name>Dabrafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed papillary thyroid carcinoma, including its variants, such as
             tall cell PTC or poorly differentiated thyroid carcinoma, that is metastatic or
             unresectable AND harbors a BRAF V600E mutation

          -  Evaluable disease, as defined by at least one lesion that can be accurately measured
             in at least one dimension on CT scan or ultrasound, if present in the neck

          -  Radioiodine-refractory disease

          -  Life expectancy &gt; 6 months

          -  Able to swallow and retain oral medication

          -  Normal organ and marrow function

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Previous treatment with a specific BRAF or MEK inhibitor

          -  Receiving any other study agents

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to GSK2118436, bovine TSH, mannitol or iodine

          -  Active gastrointestinal disease or other condition that will interfere significantly
             with the absorption of drugs

          -  History of known glucose-6-phosphate dehyrogenase (G6PD) deficiency

          -  Corrected QT interval &gt;/= 480 msecs; history of acute coronary syndromes (including
             unstable angina), coronary angioplasty, or stenting within the past 24 weeks; Class
             II, III, or IV heart failure, abnormal cardiac valve morphology; or history of known
             cardiac arrhythmias

          -  Taking herbal remedies

          -  Subjects with significant symptoms from their thyroid cancer, or have a large burden
             of rapidly progressive iodine-refractory PTC who are in need of other systemic
             therapy, as judged by their treating physician

          -  Uncontrolled current illness including, but not limited to: ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that
             would limit compliance with study requirements

          -  History of a different malignancy unless disease-free for at least 5 years and deemed
             to be at low risk for recurrence

          -  HIV-positive on combination antiretroviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Rothenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25549723</url>
    <description>pubmed url for article</description>
  </link>
  <results_reference>
    <citation>Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015 Mar 1;21(5):1028-35. doi: 10.1158/1078-0432.CCR-14-2915. Epub 2014 Dec 30.</citation>
    <PMID>25549723</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>January 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Lori J. Wirth, MD</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>Tall cell PTC</keyword>
  <keyword>Poorly differentiated thyroid carcinoma</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 2012-July 2013 Location: Massachusetts General Hospital Cancer Center Medical Clinic Number of patients recruited: 10 Recruitment goal: 10</recruitment_details>
      <pre_assignment_details>All patients recruited were enrolled, and all patients completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2118436</title>
          <description>Note: This is a single arm feasibility study.
Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
GSK2118436: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 25 Iodine-131 Scan</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 37 Iodine-131 Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2118436</title>
          <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of tumor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Classic papillary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tall cell papillary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clear cell papillary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior radioiodine treatments per patient</title>
          <units>treatments</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior surgeries per patient (not including initial thyroidectomy)</title>
          <units>surgeries</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior external-beam radiotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior targeted therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increased Radioiodine Uptake</title>
        <description>Number of patients with radioiodine-refractory metastatic BRAF V600E-mutant PTC who have increased radioiodine uptake in their disease sites while on dabrafenib. Radioiodine uptake is assessed by whole body scan and areas of interest are identified by nuclear medicine physicians.</description>
        <time_frame>25 days after start of Dabrafenib (GSK2118436)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2118436</title>
            <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.</description>
          </group>
        </group_list>
        <measure>
          <title>Increased Radioiodine Uptake</title>
          <description>Number of patients with radioiodine-refractory metastatic BRAF V600E-mutant PTC who have increased radioiodine uptake in their disease sites while on dabrafenib. Radioiodine uptake is assessed by whole body scan and areas of interest are identified by nuclear medicine physicians.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Analysis as Number of Participants With Adverse Events</title>
        <description>To evaluate the safety and tolerability, as determined by adverse event and serious adverse event reporting, of GSK2118436 in combination with whole body iodine scans (all patients) and treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake).</description>
        <time_frame>2 years</time_frame>
        <population>All patients completed dabrafenib without dose modification.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2118436</title>
            <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Analysis as Number of Participants With Adverse Events</title>
          <description>To evaluate the safety and tolerability, as determined by adverse event and serious adverse event reporting, of GSK2118436 in combination with whole body iodine scans (all patients) and treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake).</description>
          <population>All patients completed dabrafenib without dose modification.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Experienced an Adverse Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Experienced a Serious Adverse Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Experienced a Grade 3, 4, or 5 Adverse Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit as Measured by Change in Tumor Size</title>
        <description>To evaluate clinical benefit as measured by objective response rate per modified RECIST 1.1, which assesses changes in size of measurable tumors. (per RECIST, a partial response (PR) = at least 30% decrease in size of tumor; progressive disease (PD) = at least 20% increase in size of tumor; stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2118436</title>
            <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
GSK2118436: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit as Measured by Change in Tumor Size</title>
          <description>To evaluate clinical benefit as measured by objective response rate per modified RECIST 1.1, which assesses changes in size of measurable tumors. (per RECIST, a partial response (PR) = at least 30% decrease in size of tumor; progressive disease (PD) = at least 20% increase in size of tumor; stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Disease by RECIST</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease by RECIST</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response by RECIST</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Complete the Study With Minimal Delays and no Dose Reductions</title>
        <description>To determine the feasibility of: (a) administering GSK2118436 for 28 days in patients with BRAF V600E-mutant PTC, prior to whole body iodine scanning (all patients); and (b) administering GSK2118436 for an additional 14 days, prior to administering treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake after 28 days of treatment).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2118436</title>
            <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
GSK2118436: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Complete the Study With Minimal Delays and no Dose Reductions</title>
          <description>To determine the feasibility of: (a) administering GSK2118436 for 28 days in patients with BRAF V600E-mutant PTC, prior to whole body iodine scanning (all patients); and (b) administering GSK2118436 for an additional 14 days, prior to administering treatment doses of radioactive iodine (patients whose tumors demonstrate significant iodine uptake after 28 days of treatment).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit as Measured by Change in Thyroglobulin Level</title>
        <description>To evaluate clinical benefit as measured by change in serum tumor marker, thyroglobulin. Rising thyroglobulin is generally indicative of tumor growth.</description>
        <time_frame>3 months after radioiodine therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2118436</title>
            <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit as Measured by Change in Thyroglobulin Level</title>
          <description>To evaluate clinical benefit as measured by change in serum tumor marker, thyroglobulin. Rising thyroglobulin is generally indicative of tumor growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>decrease in serum thyroglobulin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>increase in serum thryoglobulin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK2118436</title>
          <description>Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
GSK2118436: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Creatinine Increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Changes</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysethesias</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lori J. Wirth</name_or_title>
      <organization>Massachusetts General Hospital Cancer Center</organization>
      <phone>617 724 4000</phone>
      <email>lwirth@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

